New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers
New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers
复制标题
DOI：
10.1016/j.ijpharm.2010.10.007
复制
发表时间：
2010-12-15
影响因子：
5.8
通讯作者：
Demetzos, Costas
中科院分区：
文献类型：
--
作者：
Gardikis, Konstantinos;Tsimplouli, Chrisiida;Demetzos, Costas
从1960年代末开始。药物递送领域已经集中于创造具有改进性质的新制剂，并非常关注药物从载体中的释放。脂质体和树枝状聚合物是研究最多的两种药物载体。最近已经发表了结合脂质体和树枝状聚合物技术的调节性脂质体控制释放系统（MLCRS）以及脂质体锁定树枝状聚合物（LLDs）技术，其被认为是一类MLCRS。嵌合先进的药物递送纳米系统（chi-aDDnss）可以被定义为混合纳米系统，由于使用的生物纳米材料的组合，并可以提供作为药物载体的优势。这项工作涉及生产两个新的chi-aDDnss纳入新合成的树枝状大分子PG 1。两种制剂中的一种具有与商业脂质体药物“Myocet”相同的药物组成。将阿霉素（Dox）掺入常规（不含树枝状聚合物）脂质体制剂和相应的chi-aDDnSs中，并评估其理化特性、体外药物释放和对人癌细胞系的体外细胞毒性。结果显示，与Myocet复制品相比，多柔比星从chi-aDDnS的调节释放效果不同。所有chi-aDDnss的药理学细胞毒性与常规脂质体系统非常接近。(C)出版社：Elsevier B. V.
Since the late 1960s. the field of drug delivery has focused on the creation of new formulations with improved properties, taking much attention to drug release from the carrier. Liposomes and dendrimers represent two of the most studied drug carriers. A Modulatory Liposomal Controlled Release System (MLCRS) combining liposomal and dendrimeric technology has been recently published as well as Liposomal locked-in Dendrimers (LLDs) technology which was considered to be a class of MLCRSs. Chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) can be defined as mixed nanosystems due to the combination of the bionanomaterials used and can offer advantages as drug carriers. This work deals with the production of two new chi-aDDnSs incorporating the newly synthesized dendrimer PG1. One of the two formulations bears the exact lipidic composition as the commercial liposomal drug "Myocet". Doxorubicin (Dox) was incorporated into conventional (free of dendrimer) liposomal formulations and into the corresponding chi-aDDnSs, and the physicochemical characteristics, the in vitro drug release and the in vitro cytotoxicity against human cancer cell lines were assessed. The results revealed a different modulation release effect of doxorubicin from the chi-aDDnS, compared to the Myocet replica. Pharmacological cytotoxicity concerning all the chi-aDDnSs was very close to that of the conventional liposomal systems. (C) 2010 Published by Elsevier B.V.